Bg pattern

FLUTICASONE CIPLA 250 micrograms/inhalation suspension for inhalation in pressurized container

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use FLUTICASONE CIPLA 250 micrograms/inhalation suspension for inhalation in pressurized container

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Patient Information Leaflet

Fluticasona Cipla 250 micrograms/inhalation suspension for inhalation in a pressurized container

Fluticasona, propionate

Read the entire leaflet carefully before starting to use this medication, as it contains important information for you.

  • Keep this leaflet, as you may need to read it again.
  • If you have any doubts, consult your doctor, pharmacist, or nurse.
  • This medication has been prescribed to you only, and you should not give it to others, even if they have the same symptoms as you, as it may harm them.
  • If you experience side effects, consult your doctor, pharmacist, or nurse, even if they are possible side effects not listed in this leaflet. See section 4.

Contents of the leaflet:

  1. What is Fluticasona Cipla and what is it used for
  2. What you need to know before starting to use Fluticasona Cipla
  3. How to use Fluticasona Cipla
  4. Possible side effects
  5. Storage of Fluticasona Cipla
  6. Container contents and additional information

1. What is Fluticasona Cipla and what is it used for

This medication contains the active substance fluticasone propionate, which belongs to a group of medications called corticosteroids.

Fluticasona Cipla acts by reducing inflammation in the lungs. This helps to prevent asthma attacks in patients who need regular treatment. This medication takes effect between 4 to 7 days, so it is very important to use it regularly.

Fluticasona Cipla is not indicated for treating acute asthma attacks in which sudden shortness of breath occurs. In such cases, another medication will be needed to treat the acute attacks.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before starting to use Fluticasona Cipla

Do not use Fluticasona Cipla:

  • if you are allergic to fluticasone propionate or any of the other components of this medication (listed in section 6).

Warnings and precautions

Stop using Fluticasona Cipla immediately

  • if you experience difficulty breathing with an immediate increase in wheezing just after taking a dose of this medication.

Consult your doctor, pharmacist, or nurse before starting to use Fluticasona Cipla:

  • if you have ever received treatment for tuberculosis (TB),
  • if you have a history of diabetes mellitus (since fluticasone may increase blood glucose levels),
  • if you have used high doses of this medication for a prolonged period and experience the following symptoms:
  • weight gain and rounding of the face (moon face) (Cushing's syndrome),
  • vague symptoms such as abdominal pain, nausea, diarrhea, headache, or drowsiness (suppressed adrenal function, acute adrenal crisis). These symptoms are more likely during an infection, such as viral infections or stomach upset,
  • bone loss,
  • eye problems (cataracts and glaucoma),
  • growth retardation (this occurs mainly in children and adolescents).

If you are unsure about any of the above, consult your doctor, nurse, or pharmacist before using Fluticasona Cipla.

Contact your doctor if you experience blurred vision and other visual disturbances.

Using Fluticasona Cipla with other medications

Tell your doctor or pharmacist if you are taking, have recently taken, or may need to take other medications, including those obtained without a prescription. In particular, inform your doctor or pharmacist if you are taking any of the following medications:

  • medications used to treat various types of infections, such as ketoconazole, clarithromycin, telithromycin, atazanavir, indinavir, nelfinavir, or saquinavir.
  • corticosteroid tablets, along with the Fluticasona Cipla inhaler or have just finished treatment with corticosteroid tablets. You should carry a steroid warning card, as there is a possibility of adrenal function disorder, especially during stressful situations such as a serious accident or if you are undergoing surgery, and your doctor may decide to administer extra corticosteroids for a while.
  • Some medications may increase the effects of Fluticasona Cipla, and your doctor may want to monitor you closely if you are taking those medications (including some HIV medications: ritonavir, cobicistat)

If you are unsure about any of the above, consult your doctor or pharmacist before taking Fluticasona Cipla.

Pregnancy, breastfeeding, and fertility

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.

Driving and using machines

It is unlikely that Fluticasona Cipla will affect your ability to drive or use tools or machinery.

3. How to use Fluticasona Cipla

Fluticasona Cipla is available in two different dose presentations for inhalation use. Your doctor will decide on the dose of the medication you need. Follow the administration instructions for this medication exactly as indicated by your doctor. If in doubt, consult your doctor, nurse, or pharmacist again.

Using this medication

  • Fluticasona Cipla can be used with a Volumatic inhalation chamber in the case of patients who have difficulty releasing a dose (puff) of the medication just after starting to inhale.
  • The initial dose will be the one indicated according to the severity of the disease. Your doctor will monitor your treatment to decrease the dose to the lowest dose that effectively controls your asthma.

Adults and adolescents over 16 years:

The recommended dose is 50 to 500 micrograms twice a day.

Use in children

The use of Fluticasona Cipla is not recommended in children under 16 years.

If you are using high doses of inhaled corticosteroids for a prolonged period, you may need more corticosteroids, for example, during stressful situations such as a traffic accident or before surgery. Your doctor may decide to prescribe extra corticosteroids during these situations.

Instructions for use

Your doctor, nurse, or pharmacist should teach you how to use your inhaler. They should check periodically how you use it. Improper use of Fluticasona Cipla or not using it as prescribed may result in your asthma not improving as it should.

The medication is packaged in a pressurized cartridge, inside a plastic casing with a mouthpiece. To avoid clogging the inhaler, it is essential to clean it at least once a week.

Checking the inhaler

  1. Before using the inhaler for the first time, check that it works correctly. Remove the mouthpiece cover by gently squeezing the sides with your thumb and index finger and pulling it off.
  2. To check that the inhaler is working correctly, shake it well, direct the mouthpiece away from you, and press the cartridge to release four puffs into the air. When you have not used the inhaler for a week or a longer period, release two puffs into the air.

Using the inhaler

Just before using the inhaler, start breathing in as slowly as possible.

  1. You can do this standing or sitting.
  1. Remove the mouthpiece cover. Inspect the inside and outside of the mouthpiece to ensure it is clean and free of particles (figure A).

Hand holding an auto-injector with the tip pointing upwards preparing to inject into the thigh

3 Shake the inhaler 4 or 5 times to ensure the elimination of any foreign particles and that the inhaler contents are properly mixed (figure B).

Hand holding an inhaler with the mouthpiece pointing downwards and arrows indicating pressure to dispense the medication

4 Hold the inhaler in a vertical position with your thumb at the base, below the mouthpiece. Expel as much air from your lungs as possible (figure C). Do not inhale yet.

Person inhaling medication with a mouth inhaler, black arrows indicating the direction of airflow

5 Place the mouthpiece of the inhaler between your teeth and close your lips around the mouthpiece. Do not bite it (see figure D).

Profile of a human head using an inhaler with arrows indicating the direction of airflow into the mouth

6 Inhale through your mouth and, just after starting to take air, press the top of the cartridge to release a dose of the medication. Continue inhaling deeply and steadily (figure D).

7 Hold your breath, remove the inhaler from your mouth, and remove your finger from the top of the inhaler. Continue holding your breath for a few seconds or as long as possible (figure E).

Person with a surgical mask showing the application area under the chin and a line indicating the injection site

8 If your doctor has indicated that you should take two inhalations, wait approximately half a minute before applying another inhalation and repeat steps 3 to 7.

9 Afterward, rinse your mouth with water and spit it out. This may help prevent certain side effects in the mouth and throat. You can also brush your teeth.

10 Immediately after using the inhaler, always replace the mouthpiece cover so that it does not collect dust. Replace the cover by pushing it firmly until you hear a click as it snaps into place.

It is recommended that you practice in front of a mirror the first few times. If you observe a "mist" coming out of the top of the inhaler or from the corners of your mouth, you should start again.

It may be helpful for older children or people with little hand strength to hold the inhaler with both hands. Place your index fingers on the top of the inhaler and your thumbs on the bottom, below the mouthpiece. Your doctor, nurse, or pharmacist will show you how to do this.

Cleaning the inhaler

To avoid clogging the inhaler, you should clean it at least once a week.

To do this:

  • Remove the mouthpiece cover.
  • Do not remove the metal cartridge from the plastic casing.
  • Clean the inside and outside of the mouthpiece and the plastic casing with a dry cloth or paper towel
  • Replace the mouthpiece cover.

Do not submerge the metal cartridge in water.

If you use more Fluticasona Cipla than you should

If you have used a higher dose than recommended, consult your doctor as soon as possible.

It is essential to take the dose indicated in the prescription or as your doctor has indicated. Do not increase or decrease the dose without consulting your doctor first.

In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 915 620 420, indicating the medication and the amount ingested.

If you forget to use Fluticasona Cipla

  • Take your next dose when it is due.
  • Do not take a double dose to make up for the forgotten dose.

If you stop treatment with Fluticasona Cipla

Do not stop your treatment, even if you feel better, unless your doctor tells you to. Patients who have been treated with high doses of corticosteroids for a prolonged period should not stop taking the medication without consulting their doctor first, as their asthma may worsen. Abruptly stopping treatment can also cause discomfort and may lead to symptoms such as vomiting, numbness, nausea, headache, fatigue, loss of appetite, decreased blood glucose levels, and convulsions.

If you have any further questions about the use of this medication, ask your doctor, nurse, or pharmacist.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medications, this medication can cause side effects, although not everyone will experience them. If you experience any of the following serious side effects, stop using this medication and consult your doctor immediately. You may need urgent medical treatment.

  • Allergic reaction (may affect up to 1 in 100 patients) or severe allergic reactions (may affect up to 1 in 10,000 patients), signs include skin rash, redness, itching, or "hives" and swelling of the face, lips, mouth, tongue, or throat, which can cause difficulty swallowing or breathing, pruritic rash, feeling of fainting and dizziness, and collapse, respectively.
  • If your breathing or wheezing worsens just after using the inhaler.

Other side effects are:

Very common(may affect more than 1 in 10 people)

  • thrush in the mouth and throat.

Common(affect less than 1 in 10 people)

  • throat irritation and hoarseness
  • bruising
  • neumonia (lung infection) in patients with COPD

Tell your doctor if you experience any of the following symptoms while inhaling Fluticasona Cipla; they could be symptoms of a lung infection:

  • fever or chills
  • increased mucus production, change in mucus color
  • increased coughing or increased difficulty breathing

Very rare(affect less than 1 in 10,000 people)

  • difficulty sleeping or feelings of worry, overexcitement, and irritability (these effects occur mainly in children),
  • may increase blood sugar levels,
  • using high doses of Fluticasona Cipla for prolonged periods may cause: adrenal suppression, acute adrenal crisis, Cushing's syndrome, decreased bone density, eye problems (such as cataracts and glaucoma), and growth retardation in children and adolescents (see Section 2 "Warnings and precautions").

To help prevent these symptoms, your doctor will ensure that you are using the lowest dose of corticosteroids that controls your asthma.

Frequency not known(cannot be estimated from available data)

  • depression,
  • feeling of restlessness or nervousness (these effects occur mainly in children),
  • blurred vision.

Reporting side effects

If you experience any side effects, consult your doctor or pharmacist, even if they are possible side effects not listed in this leaflet. You can also report them directly through the Spanish Medication Monitoring System https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medication.

5. Storage of Fluticasona Cipla

Keep this medication out of sight and reach of children.

Clean your inhaler weekly and if it becomes blocked, follow the instructions described in the "Cleaning the inhaler" section.

Do not use this medication after the expiration date shown on the label and carton after EXP. The expiration date is the last day of the month indicated.

The cartridge contains a pressurized liquid. Do not expose to temperatures above 50°C. Do not puncture the cartridge. Do not refrigerate or freeze. Protect from very low temperatures and direct sunlight.

If the inhaler is very cold, remove the metal cartridge from the plastic casing and warm it in your hands for a few minutes before use. Never use other methods to heat it.

The metal cartridge is pressurized. Do not puncture, break, or burn it, even if it appears to be empty.

Medications should not be disposed of through wastewater or household waste. Deposit the packaging and medications you no longer need at the SIGRE collection point in your pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. This will help protect the environment.

6. Container Content and Additional Information

Composition of Fluticasona Cipla

  • The active ingredient is fluticasone propionate. Each measured dose contains 250 micrograms of fluticasone propionate, which is equivalent to an emitted dose of 227 micrograms of fluticasone propionate.
  • This medication contains fluorinated greenhouse gases.
  • Each inhaler contains 12.5 g of HFC-134a (norflurane) which corresponds to 0.018 tons of CO2 equivalent (global warming potential GWP = 1430).

Appearance of the Product and Container Content

  • Fluticasona Cipla is a white suspension, contained in an aluminum alloy cartridge treated with fluorocarbon polymer, which is sealed with a dosing valve, an applicator, and a protective cap.
  • Package sizes: Single package - each package contains a bottle with 120 puffs. Multipack - wrapped with 2 or 3 packages. Hospital package - wrapped with 10 packages. Only some package sizes may be marketed.

Marketing Authorization Holder and Manufacturer

Marketing Authorization Holder

Cipla Europe NV

De Keyserlei 60C, Bus-1301,

2018, Antwerp,

Belgium

Manufacturer

S&D Pharma CZ, spol. s.r.oTheodor 28,

273 08 Pchery, (Pharmos a.s. facility),

Czech Republic

or

Cipla Europe NV

De Keyserlei 60C, Bus-1301,

2018, Antwerp,

Belgium

Local Representative

Cipla Europe NV branch in Spain,

C/ Guzmán el Bueno, 133 Edif Britannia-28003- Madrid

Spain

This medication is authorized in the Member States of the European Economic Area with the following names:

Sweden

Fluticasone Cipla 250 micrograms/dose inhalation spray, suspension

Germany

Fluticason Cipla 250 micrograms/puff pressurized inhalation, suspension

Italy

FLUTICASONE DOC 250 micrograms per actuation, pressurized suspension for inhalation

Norway

Flutikason Cipla 250 micrograms/dose inhalation aerosol, suspension

Spain

Fluticasona Cipla 250 micrograms/inhalation suspension for inhalation in a pressurized container

Date of the Last Revision of this Prospectus:January 2025

Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/

Online doctors for FLUTICASONE CIPLA 250 micrograms/inhalation suspension for inhalation in pressurized container

Discuss questions about FLUTICASONE CIPLA 250 micrograms/inhalation suspension for inhalation in pressurized container, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (69)
Doctor

Tarek Agami

General medicine 11 years exp.

Dr. Tarek Agami is a general practitioner registered in both Portugal and Israel, with broad experience in family and preventive medicine. He offers online consultations for adults and children, providing personalised support for primary care needs, chronic disease management, and everyday health concerns.

Dr. Agami received clinical training and worked in leading medical institutions in Israel (Kaplan Medical Center, Barzilai Medical Center, Wolfson Medical Center) and Portugal (European Healthcare City, Viscura Internacional, Hospital Dr. José Maria Grande, Hospital Vila Franca de Xira). His approach combines international medical standards with individualised attention to each patient.

Main areas of consultation:

  • Diagnosis and treatment of acute and chronic conditions (high blood pressure, diabetes, respiratory infections, cardiovascular symptoms)
  • Evaluation of symptoms and guidance on further diagnostic testing
  • Preventive check-ups and regular health monitoring
  • Medical support during travel or after relocation
  • Treatment adjustments and lifestyle recommendations based on your personal history
Dr. Agami provides medical support for patients using GLP-1 medications (such as Ozempic or Mounjaro) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Portugal and Israel.

Dr. Agami is committed to evidence-based, patient-centred care, ensuring that each person receives trusted medical support tailored to their health goals.

Camera Book a video appointment
€69
5.0 (63)
Doctor

Nuno Tavares Lopes

Family medicine 18 years exp.

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

Camera Book a video appointment
€59
5.0 (17)
Doctor

Anastasiia Shalko

Family medicine 13 years exp.

Dr. Anastasiia Shalko is a general practitioner with a background in both paediatrics and general medicine. She graduated from Bogomolets National Medical University in Kyiv and completed her paediatric internship at the P.L. Shupyk National Medical Academy of Postgraduate Education. After working as a paediatrician in Kyiv, she relocated to Spain, where she has been practising general medicine since 2015, providing care for both adults and children.

Her work focuses on urgent, short-term medical concerns – situations where patients need quick guidance, symptom assessment and clear next steps. She helps people understand whether their symptoms require in-person evaluation, home management or a change in treatment. Common reasons for booking an online consultation include:

  • acute respiratory symptoms (cough, sore throat, runny nose, fever)
  • viral illnesses such as colds and seasonal infections
  • gastrointestinal complaints (nausea, diarrhoea, abdominal pain, gastroenteritis)
  • sudden changes in how a child or adult feels
  • questions about existing treatment and whether adjustments are needed
  • renewal of prescriptions when clinically appropriate
Dr. Shalko works specifically with urgent and short-term problems, providing practical recommendations and helping patients determine the safest next step. She explains symptoms clearly, guides patients through decision-making and offers straightforward medical advice for everyday acute issues.

She does not provide long-term management of chronic conditions, ongoing follow-up or comprehensive care plans for complex long-term illnesses. Her consultations are designed for acute symptoms, sudden concerns and situations where timely medical input is important.

With clinical experience in both paediatrics and general medicine, Dr. Shalko confidently supports adults and children. Her communication style is clear, simple and reassuring, helping patients feel informed and supported throughout the consultation.

Camera Book a video appointment
€50
5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80

Frequently Asked Questions

Is a prescription required for FLUTICASONE CIPLA 250 micrograms/inhalation suspension for inhalation in pressurized container?
FLUTICASONE CIPLA 250 micrograms/inhalation suspension for inhalation in pressurized container requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in FLUTICASONE CIPLA 250 micrograms/inhalation suspension for inhalation in pressurized container?
The active ingredient in FLUTICASONE CIPLA 250 micrograms/inhalation suspension for inhalation in pressurized container is fluticasone. This information helps identify medicines with the same composition but different brand names.
How much does FLUTICASONE CIPLA 250 micrograms/inhalation suspension for inhalation in pressurized container cost in pharmacies?
The average pharmacy price for FLUTICASONE CIPLA 250 micrograms/inhalation suspension for inhalation in pressurized container is around 31.47 EUR. Prices may vary depending on the manufacturer and dosage form.
Who manufactures FLUTICASONE CIPLA 250 micrograms/inhalation suspension for inhalation in pressurized container?
FLUTICASONE CIPLA 250 micrograms/inhalation suspension for inhalation in pressurized container is manufactured by Cipla Europe. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of FLUTICASONE CIPLA 250 micrograms/inhalation suspension for inhalation in pressurized container online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether FLUTICASONE CIPLA 250 micrograms/inhalation suspension for inhalation in pressurized container is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to FLUTICASONE CIPLA 250 micrograms/inhalation suspension for inhalation in pressurized container?
Other medicines with the same active substance (fluticasone) include FLIXOTIDE 250 micrograms/inhalation, pressurized inhaler suspension, FLIXOTIDE 50 micrograms/inhalation, pressurized inhaler suspension, FLIXOTIDE ACCUHALER 100 micrograms/inhalation, powder for inhalation. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media